Bax:Bcl2 Cancer Research Results
Bax:Bcl2, Bax:Bcl2 ratio: Click to Expand ⟱
| Source: |
| Type: |
Bax and Bcl-2 are the major members of Bcl-2 family that play a key role in tumor progression or inhibition of intrinsic apoptotic pathway triggered by mitochondrial dysfunction.
Bax/Bcl-2 ratio is typically significantly lower in tumors.
|
Cerv, Cervical Cancer: Click to Expand ⟱
Scientific Papers found: Click to Expand⟱
tumCV↓, TumCCA↑, DNA-PK↑, ChrMod↝, MMP↓, Bax:Bcl2↑, Cyt‑c↓, Casp9↑, Casp3↑, ROS↑, TumCMig↓,
Cyt‑c↑, Bax:Bcl2↑, Casp3↑, Casp9↑, Casp8↑, cl‑PARP↑, cMyc↓, hTERT/TERT↓, cycD1/CCND1↓, CDK4↓, P53↑, P21↑, TumCP↓, Apoptosis↓, selectivity↑,
Showing Research Papers: 1 to 2 of 2
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2
Pathway results for Effect on Cancer / Diseased Cells:
Redox & Oxidative Stress(tgid=1) ⓘ
ROS↑, 1,
Mitochondria & Bioenergetics(tgid=3) ⓘ
MMP↓, 1,
Core Metabolism/Glycolysis(tgid=4) ⓘ
cMyc↓, 1,
Cell Death(tgid=5) ⓘ
Apoptosis↓, 1, Bax:Bcl2↑, 2, Casp3↑, 2, Casp8↑, 1, Casp9↑, 2, Cyt‑c↓, 1, Cyt‑c↑, 1, hTERT/TERT↓, 1,
Transcription & Epigenetics(tgid=7) ⓘ
ChrMod↝, 1, tumCV↓, 1,
DNA Damage & Repair(tgid=10) ⓘ
DNA-PK↑, 1, P53↑, 1, cl‑PARP↑, 1,
Cell Cycle & Senescence(tgid=11) ⓘ
CDK4↓, 1, cycD1/CCND1↓, 1, P21↑, 1, TumCCA↑, 1,
Migration(tgid=13) ⓘ
TumCMig↓, 1, TumCP↓, 1,
Drug Metabolism & Resistance(tgid=21) ⓘ
selectivity↑, 1,
Clinical Biomarkers(tgid=22) ⓘ
hTERT/TERT↓, 1,
Total Targets: 24
Pathway results for Effect on Normal Cells:
Total Targets: 0
Scientific Paper Hit Count for: Bax:Bcl2, Bax:Bcl2 ratio
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:29 Cells:% prod#:% Target#:352 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid
Home Page